Results 81 to 90 of about 4,268 (199)

The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections

Viruses
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections.
Erik De Clercq
doaj   +1 more source

Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study

Background. The life expectancy of people with human immunodeficiency virus (PWH) has significantly increased, thanks to combined antiretrovirals with improved potency and tolerability.
Marzolini, C., Marzolini, C, Bettonte, S., Battegay, M., Berton, M, Bettonte, S, Stader, F., Battegay, M, Stader, F, Berton, M.   +9 more
core   +1 more source

Contribución de cabotegravir + rilpivirina de acción prolongada al tratamiento de la infección por VIH-1

, 2022
Resumen Objetivo: Determinar la contribución de valor de cabotegravir + rilpivirina, el primer tratamiento antirretroviral inyectable de acción prolongada, utilizando metodología de análisis de decisión multicriterio.
Vallejo-Aparicio,Laura Amanda, Calleja-Hernández,Miguel Ángel, Hernández-Novoa,Beatriz, Badia,Xavier, Martinez-Sesmero,José Manuel   +4 more
core   +1 more source

Cabotegravir and Rilpivirine

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Pittsburgh Sleep Quality Index (PSQI) Changes in Virologically Suppressed People Living with HIVSwitching to Long-Acting Cabotegravir and Rilpivirine

Biomedicines
Background: Limited evidence is available about sleep quality changes associated with the use of Cabotegravir (CAB), a new, long-acting (LA) antiretroviral (ARV) drug belonging to the class of Integrase Strand Transfer Inhibitors (INSTIs).
Nicolò De Gennaro, Mariacristina Poliseno, Angelo Dargenio, Flavia Balena, Deborah Fiordelisi, Vito Spada, Greta Romita, Giacomo Guido, Francesco Di Gennaro, Giuseppe Bruno, Mariantonietta Purgatorio, Giovanni Battista Buccoliero, Annalisa Saracino   +12 more
doaj   +1 more source

Clinical LC-MS/MS Assay for Therapeutic Drug Monitoring of Cabotegravir in Venous or Self-collected Capillary Plasma

<b><i>Aim</i></b> Long-acting injectable cabotegravir (CAB-LA) is used for HIV treatment and pre-exposure prophylaxis (PrEP), but substantial inter-individual pharmacokinetic variability, drug-drug interactions, and a prolonged ...
Jason Zucker, Nadia Nguyen, Alex Lyashchenko, Jordan B. Metz, Mark Marzinke, Michael Yin, Kathrine Meyers, Serge Cremers, Alexa DeJesus, Kevin Wang, Christina Hijiya   +10 more
core   +1 more source

Cabotegravir Sodium

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges

New England Journal of Medicine
Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking.We conducted an open-label, randomized trial involving persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per ...
Aadia I. Rana, Lu Zheng, Jose Castillo-Mancilla, Yajing Bao, Sara Sieczkarski, Kristina M. Brooks, Jordan E. Lake, Carl Fichtenbaum, Sonya L. Heath, Pablo F. Belaunzaran-Zamudio, Karin Klingman, Lawrence Fox, Tia Morton, Michael Stirratt, Jonathan Z. Li, Edward P. Acosta, Charles Venuto, Omar Galárraga, Steven Shoptaw, David Wohl, Madison Green, Ceora Beijer, Kathie Ferbas, Cheryl Jennings, Katherine Shin, Romina Collahua, Michael Dorosh, Paul Wannamaker, Ronald D’Amico, Kimberly Smith, William Spreen, Kati Vandermeulen, Rodica Van Solingen-Ristea, Chanelle Wimbish, Karen T. Tashima, Raphael J. Landovitz   +35 more
openaire   +3 more sources

Southern African HIV Clinicians Society guideline on pre-exposure prophylaxis to prevent HIV

Southern African Journal of HIV Medicine
No Abstract available.
Pippa Macdonald, Gonasagrie Nair, Camilla Wattrus, Saiqa Mullick, Melanie Pleaner, Elzette Rousseau, Hasina Subedar, Dvora Joseph-Davey, Johan Hugo, Sinead Delany-Moretlwe, Linda-Gail Bekker   +10 more
doaj   +1 more source

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Emerging Infectious Diseases
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine ...
Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi   +8 more
doaj   +1 more source